Clinical Validation of a Blood-Based Predictive Test for Stratification of Response to Tumor Necrosis Factor Inhibitor Therapies in Rheumatoid Arthritis Patients
Objectives: For rheumatoid arthritis (RA) patients failing to achieve treatment targets with conventional synthetic disease-modifying antirheumatic drugs, tumor necrosis factor (TNF)-? inhibitors (anti-TNF therapies) are the primary first-line biologic therapy. In a cross-cohort, cross-platform stud...
Format: | Article |
---|---|
Language: | English |
Published: |
Mary Ann Liebert
2020-07-01
|
Series: | Network and Systems Medicine |
Online Access: | https://www.liebertpub.com/doi/full/10.1089/NSM.2020.0007 |
Similar Items
-
Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Rheumatoid Arthritis
by: Inês P. Perpétuo, et al.
Published: (2017-01-01) -
The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis
by: Natalia Vladimirovna Chichasova
Published: (2014-12-01) -
Intra-articular therapy with methotrexate or tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic review
by: Megan M. Sullivan, et al.
Published: (2021-09-01) -
USE OF TUMOR NECROSIS FACTOR-A INHIBITORS IN RHEUMATOID ARTHRITIS: TOPICAL ASPECTS
by: E L Luchikhina, et al.
Published: (2008-12-01) -
USE OF TUMOR NECROSIS FACTOR-A INHIBITORS IN RHEUMATOID ARTHRITIS: TOPICAL ASPECTS
by: E L Luchikhina, et al.
Published: (2008-12-01)